retatrutide expected approval date approval: FDA status, clinical trial results, and when it could be available Chapter One Wellness Center |
Description
Overall, the GLP-1RA group had a 10% decrease in depression risk compared to the DPP4i group
It definitely helped to give me the kick start I needed for weight loss but I can do it without so I'm glad I stopped it when I did
The pharmacotherapy it offers (semaglutide) has the strongest weight-loss evidence base of any currently available anti-obesity agent
Individuals at risk of AD or with diabetes may be in the early or middle biological stage of AD, offering a greater opportunity for GLP-1RAs to provide neuroprotection
doi: 10.1586/17474124.2016.1129898
